Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2025)
Pyxis Oncology (PYXS) reported Non Operating Investment Income of -$16000.0 for Q4 2025, up 91.16% year-over-year from -$8369.9 in Q4 2024, and down 121.62% quarter-over-quarter from $74000.0 in Q3 2025.
Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 3 years of Non Operating Investment Income data on file, last reported at -$16000.0 in Q4 2025.
- Non Operating Investment Income for Q4 2025 came in at -$16000.0, up 91.16% year-over-year; the trailing twelve-month figure through Dec 2025 was -$117000.0 (down 209.35% YoY), and the FY2025 annual result was -$117000.0, down 209.35% from the prior year.
- Non Operating Investment Income eased to -$16000.0 in Q4 2025 per PYXS's latest filing, from $74000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $696000.0 in Q1 2023 and troughed at -$781000.0 in Q2 2023.
- A 3-year average of $4416.7 and a median of -$31000.0 in 2023 frame the typical range for Non Operating Investment Income.
- On a YoY basis, Non Operating Investment Income climbed as much as 2365.0% in 2024 and fell as far as 207.74% in 2024.
- A 3-year view of Non Operating Investment Income shows it stood at $168000.0 in 2023, then tumbled by 207.74% to -$181000.0 in 2024, then jumped by 91.16% to -$16000.0 in 2025.
- Business Quant data shows PYXS's Non Operating Investment Income at -$16000.0 in Q4 2025, $74000.0 in Q3 2025, and -$54000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Sep 30, 2023 | -20,000.00 |